Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned a consensus rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $9.80.

Several equities research analysts recently commented on the company. Leerink Partners upped their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th.

Aquestive Therapeutics Trading Up 5.5 %

Shares of AQST stock opened at $4.81 on Tuesday. The stock has a market cap of $438.58 million, a price-to-earnings ratio of -10.69 and a beta of 2.82. The stock has a 50-day moving average of $4.99 and a 200-day moving average of $3.93. Aquestive Therapeutics has a 1-year low of $1.84 and a 1-year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same period last year, the firm posted ($0.03) earnings per share. Sell-side analysts forecast that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Institutional Trading of Aquestive Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. purchased a new stake in shares of Aquestive Therapeutics in the second quarter worth approximately $27,000. nVerses Capital LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth approximately $28,000. SG Americas Securities LLC purchased a new stake in shares of Aquestive Therapeutics in the first quarter worth approximately $54,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Aquestive Therapeutics during the second quarter valued at approximately $76,000. Finally, Financial Advocates Investment Management increased its position in shares of Aquestive Therapeutics by 70.0% during the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after acquiring an additional 14,000 shares during the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.